SecSonar.com

Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Ocular Therapeutix, Inc. (OCUL) is a Biotechnology company based in US with a market capitalization of $2B. Revenue declined 18.7% year-over-year and free cash flow was negative at -$216.9M. This page tracks OCUL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 274 employees · IPO Jul 25, 2014

Valuation

Valuation & price

$9.16 · as of May 17, 2026 · -43.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.09

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$16.11$11.49$6.88Jul 25Dec 25Jul 26Jul 7, 25$9.61Jul 9, 25$10.76Jul 11, 25$11.03Jul 15, 25$11.09Jul 17, 25$11.38Jul 21, 25$11.52Jul 23, 25$11.96Jul 25, 25$12.21Jul 29, 25$11.75Jul 31, 25$11.58Aug 4, 25$12.35Aug 6, 25$12.50Aug 11, 25$12.56Aug 13, 25$12.50Aug 15, 25$12.62Aug 19, 25$12.14Aug 21, 25$12.13Aug 25, 25$11.87Aug 27, 25$12.32Aug 29, 25$12.21Sep 3, 25$12.94Sep 5, 25$13.60Sep 9, 25$12.76Sep 11, 25$12.77Sep 16, 25$12.44Sep 18, 25$12.71Sep 22, 25$12.20Sep 24, 25$12.56Sep 26, 25$12.53Sep 30, 25$11.69Oct 2, 25$11.06Oct 6, 25$10.97Oct 8, 25$11.91Oct 10, 25$11.78Oct 14, 25$11.23Oct 16, 25$12.20Oct 21, 25$11.77Oct 23, 25$11.44Oct 27, 25$11.55Oct 29, 25$11.48Oct 31, 25$11.66Nov 4, 25$10.90Nov 6, 25$10.63Nov 10, 25$10.83Nov 12, 25$11.49Nov 14, 25$11.30Nov 18, 25$11.76Nov 20, 25$11.72Nov 25, 25$12.13Nov 28, 25$12.15Dec 2, 25$11.25Dec 4, 25$12.43Dec 8, 25$16.11Dec 10, 25$15.41Dec 12, 25$14.56Dec 16, 25$14.39Dec 18, 25$12.98Dec 22, 25$12.96Dec 24, 25$12.71Dec 29, 25$12.30Jan 2, 26$11.82Jan 6, 26$11.25Jan 8, 26$11.38Jan 12, 26$10.69Jan 14, 26$11.07Jan 16, 26$11.27Jan 21, 26$11.42Jan 23, 26$10.27Jan 27, 26$10.85Jan 29, 26$9.95Feb 2, 26$9.15Feb 4, 26$8.55Feb 9, 26$9.43Feb 11, 26$9.16Feb 13, 26$8.88Feb 18, 26$6.88Feb 20, 26$7.78Feb 24, 26$8.96Feb 26, 26$9.59Mar 2, 26$10.98Mar 4, 26$11.04Mar 6, 26$10.27Mar 10, 26$9.87Mar 12, 26$8.87Mar 17, 26$8.68Mar 19, 26$8.27Mar 23, 26$8.10Mar 25, 26$8.33Mar 27, 26$7.55Mar 31, 26$8.47Apr 2, 26$8.49Apr 7, 26$8.34Apr 9, 26$9.30Apr 13, 26$8.86Apr 15, 26$8.91Apr 17, 26$9.82Apr 22, 26$9.66Apr 24, 26$9.49Apr 28, 26$9.32Apr 30, 26$9.37May 4, 26$9.77May 6, 26$9.71May 8, 26$9.65May 12, 26$9.16May 14, 26$9.50May 18, 26$8.38May 20, 26$8.03May 22, 26$8.23May 28, 26$9.15Jun 1, 26$8.93Jun 3, 26$8.35Jun 5, 26$8.25Jun 9, 26$8.47Jun 11, 26$8.70Jun 15, 26$8.99Jun 17, 26$9.64Jun 22, 26$9.97Jun 24, 26$9.85Jun 26, 26$9.84Jul 2, 26$9.64
$6.8852-week range$16.11
Loading valuation history…

Fundamentals

Key fundamentals

$2B

Market cap

-18.7%

Revenue growth (YoY)

87.3%

Gross margin

-$216.9M

Free cash flow (USD)

-$657.3M

Net debt

Net cash position

18.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.9MFY 2017$1.9MFY 2018$2.0MFY 2019$4.2MFY 2020$17.4MFY 2021$43.5MFY 2022$51.5MFY 2023$58.4MFY 2024$63.7MFY 2025$51.8M
$1.9M$51.8M

Free cash flow by year

2016 → 2025

FY 2016$-35.9MFY 2017$-58.7MFY 2018$-51.1MFY 2019$-79.8MFY 2020$-54.4MFY 2021$-66.7MFY 2022$-63.3MFY 2023$-76.3MFY 2024$-136.0MFY 2025$-216.9M
-$35.9M-$216.9M

Gross margin by year

2021 → 2025

FY 202189.9%FY 202291.2%FY 202391.0%FY 202491.2%FY 202587.3%
89.9%87.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCFO AppointmentJun 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing

Questions

Frequently asked questions

What is Ocular Therapeutix, Inc.'s market cap?

Ocular Therapeutix, Inc. (OCUL) has a market capitalization of $2B.

What is OCUL's P/E ratio?

A meaningful P/E ratio is not available for OCUL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is OCUL's price-to-book (P/B) ratio?

OCUL trades at 3.09 times book value per share.

Are insiders buying OCUL stock?

SEC Form 4 filings show no open-market insider buys at Ocular Therapeutix, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

NBTX

Nanobiotix S.A.

$2B

ZLAB

Zai Lab Limited

$2B

MESO

Mesoblast Limited

$2B

AUPH

Aurinia Pharmaceuticals Inc.

$2B

CLDX

Celldex Therapeutics, Inc.

$2.1B

IMNM

Immunome, Inc.

$2.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.